NTRK
Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
Bayer, NeoGenomics Launch Free NTRK Fusion Testing Program
The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.
Japanese Regulator Approves Foundation Medicine CDx for Roche's Rozlytrek in Lung Cancer
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
Premium
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.